

# Subject Index

1S, 3R-ACPD, 230

619C89

cerebral focal ischemia and, 39

increasing intravenous doses of, 324, 328

## Acute ischemic stroke

619C89 and, 324, 328

lifarizine in, 317

remacemide HCl and, 322

Ro-01-6794/706 and, 249

Acute neurodegenerative processes,

evaluating protection against, 50

Acute neuroprotection, adenosine and, 169

Adenosine, brain and, 163

Adenosine A<sub>2</sub> receptor, dopamine D<sub>2</sub> receptor and, 168

Adenosine receptor types, 164

Adhesion molecules, brain injury and, 65

Age dependence, dexamethasone and, 189

1-Aminocyclopropanecarboxylic acid (ACPC), 320

Animal model

human model and, 60

safety parameters in, 199

Antioxidant enzymes, free radicals and, 183

Antioxidants, 116

Aptiganel hydrochloride (CNS 1102), 279

Assessment approaches, 59

## Behavior, hypoxic rats and, 34

Biologically based dose-response model, 339

Biomarkers of neurotoxicity, 205

Blood pressure, CNS 1102 and, 287

Brain injury, TNF $\alpha$  and, 62

## Calcitonin gene-related peptide,

subarachnoid hemorrhage and, 299

Calcium, glucocorticoid receptors and, 134

Calcium antagonists, 119, 185

Calcium channel antagonists, depolarization and, 160

Calcium channels

presynaptic, 214

short-term regulation of, 119

use-dependent blockers of, 210

Caloric reduction, oxidative brain damage and, 308

Cannabinoid, HU-211 as, 314

Cardiopulmonary bypass,

neurophysiological test scores in, 23

Carotid endarterectomy, 23

Catalase, 184

Catecholamines, glutamine-enhanced release of, 75

Cell culture

1,4-dihydropyridine binding assay in, 122

disadvantage of, 111

Central nervous system, TNF $\alpha$  and, 63

Cerebral blood flow

adenosine and, 163

CNS 1102 and, 280

dexamethasone and, 182

Cerebral circulation, 334

Cerebral focal ischemia, 619C89 and, 39

Cerebral hypoxic injury, 31

Cerebrovascular effects, CNS 1102, 280

Channel classification and regulation, 120

Chronic administration, adenosine-based therapies and, 170

Clinical pharmacology, CNS 1102, 279

Clinical potential for neuroprotective agents, 1

Clinical syndromes, 26

CNS 1102

cerebral hemodynamic and metabolic effects of, 332

clinical pharmacology of, 279, 336

CNS 1237, use-dependent channel block and, 219

Cocaine dependence, nimodipine and, 150

"Code Stroke" alert system, 2

Corticosterone, adrenal cortical hormone receptors and, 134

Corticosterone levels, variability of, 139

Corticosterone receptors types I and II, 135

## Dendritic atrophy, nimodipine and, 312

2-Deoxyglucose, dexamethasone and, 189

Depolarization, 125

Dexamethasone, neonatal hypoxic-

ischemic brain damage and, 179

Dextrorphan HCl, safety of, 249

Diffuse axonal injury, 263

1,4-Dihydropyridines, binding of, 120

Dopamine D<sub>2</sub> receptor, adenosine A<sub>2</sub> receptor and, 168

Doppler ultrasound, 280

Dorsal root ganglion, radical scavengers and, 111

Dose-response models, 203

## Electroencephalogram (EG), recording procedures of, 145

Electrophysiology, use-dependent channel block and, 216

- Energy disrupters, 116  
Energy metabolism, 32  
Energy repletion, neuroprotective effects of, 104  
Epilepsy  
  NMDA antagonists in, 12  
  remacemide and, 277  
Event-related potential, substance abusers and, 152  
Excitatory amino acid  
  severe head trauma and, 290  
  excessive release of, 262  
Excitotoxic effects, glutamate and, 290  
Excitotoxic mechanisms, acute subdural hematoma and, 265  
Excitotoxic neuronal death, CNS 1102 and, 336  
Excitotoxicity, 98  
  neurodegenerative diseases and, 100  
**F**asting, dexamethasone and, 187  
Fluid percussion injury, 264  
Flunarizine, dexamethasone and, 185  
Focal cerebral ischemia  
  models of, 242  
  prophylactic neuroprotection in, 4, 21  
  remacemide HCl and, 322  
  small animal model of, 301  
Free fatty acids, 33  
Free radical scavengers  
  neuroprotective effects of, 102  
  side effects and safety of, 117  
Free radicals  
  adenosine and, 171  
  antioxidant enzymes and, 183  
**G** proteins, adenosine and, 172  
Gamma-aminobutyric acid (GABA), visual spatial learning in rats and, 4  
Ganglioside GM<sub>1</sub>  
  methamphetamine-induced neurotoxicity and, 311  
  perinatal brain injury and, 304  
GH<sub>4</sub>C<sub>1</sub> cells, 120  
Glial cells, effects of glutamine on, 78  
Global cerebral ischemia  
  remacemide HCl and, 322  
  models of, 238  
Glucocorticoid, 180  
  P3B and, 161  
Glucose utilization, dexamethasone effects on, 188  
Glutamate  
  CNS and, 279  
  glial cells and, 79  
  hypocapnia and, 86  
  putative excitotoxic effects of, 290  
  use-dependent blockers controlling, 210  
Glutamate antagonists, strategies for neuroprotection with, 272  
Glutamate release, 619C89 and, 328  
Glutamate uptake, endogenous adenosine and, 166  
Glutamine-enhanced glutamate release, 72  
Glycine  
  hypocapnia and, 86  
  NMDA receptor and, 320  
**H**allucinations, 619C89 and, 329  
Head injury  
  CNS 1102 and, 332  
  EAA release and, 290  
  glutamate antagonist in treatment of, 262  
Hippocampal slices, glutamate from, 75  
Hippocampus  
  adrenal cortical hormone receptors of, 134  
  hypocapnia and, 86  
  quantitative histological evaluation of neurotoxic damage in, 303  
  trimethyltin and, 54  
HU-211, neuroprotective activity of, 314  
Huntington's disease, 14  
  remacemide HCl and, 245  
Hyperglycemia, dexamethasone and, 186  
Hyperthermia, MK-801 and, 7  
Hyperventilation, brain lactate and, 86  
Hypocapnia, extracellular glutamate and glycine and, 86  
Hypotension, dextrorphan and, 254  
Hypothermia  
  hypoxic-ischemic damage and, 182  
  ischemia/reperfusion injury and, 98  
  methamphetamine neurotoxicity and, 338  
Hypoxia, intact dorsal root ganglion, 111  
Hypoxia-ischemia, dexamethasone and, 179  
Hypoxic depolarization, adenosine and, 166  
Hypoxic-ischemic brain injury, role of growth factors after, 306  
**I**mmunohistochemistry of neurotoxicity biomarkers, 50  
Infarct volume, 619C89 and, 43  
Infarction, hypoxia-ischemia and, 181  
Inflammation, TNF $\alpha$  and, 62  
Insulin-like growth factor 1, hypoxic-ischemic brain injury and, 306  
Intracranial pressure, EAA release and, 294  
Ion conductances, adenosine and, 167

- Ischemia, glutamate release blockers and, 212
- Ischemic damage, hippocampal, 263
- Ischemic stroke, multicenter clinical trials and, 2
- K**ainate, glutamate levels and, 78
- Kynurenate, glutamate levels and, 78
- L**-AP4, 230
- L-CCG1, 230
- L-channels, 120
- L-SOP, 230
- Lactate, brain, 86
- Lifarizine, acute ischemic stroke and, 317
- Limbic seizures, metabotropic glutamate receptor agonist-mediated, 230
- M**agnesium, 196
- Magnesium sulfate, acute stroke and, 315
- Mechanism, 98
- Memory retention, nimodipine and, 312
- Metabotropic glutamate receptors, 230
- Methamphetamine, glutamate levels and, 78
- Methamphetamine neurotoxicity, hypothermia and, 338
- Methemoglobinemia, 136
- Microdialysis, 291
- Middle cerebral artery occlusion (MCAO), use-dependent channel block and, 218
- Middle cerebral artery occlusion model of focal ischemia, 619C89 and, 39
- MK-801, S-PBN and, 104
- Morphometric studies, experimental design of, 47
- Muscarinic receptors, 125
- N**-channels, 120
- Neonatal brain damage, dexamethasone and, 179
- Nerve growth factors, dexamethasone and, 196
- Neurodegeneration
- adenosine A<sub>2</sub> receptors and, 167
  - excitotoxic hypothesis and, 268
- Neurodegenerative disease
- animal models of, 101
  - EAA toxicity and, 12
- Neurological deficit, 619C89 and, 45
- Neuroprotection
- 619C89 and, 42
  - radical scavengers and, 111
- Neuroprotection regimen, prophylactic pharmacologic, 22
- Neurotoxicity
- assessing human, 198
  - NMDA antagonists and, 268
- Neurotoxicity endpoints, 200
- Neurotransmitter release, adenosine analogues and, 165
- Neurotrauma, CGS 19755 and, 272
- Nimodipine
- auditory rare event monitoring task and, 153
  - cerebral blood flow and, 334
  - EEG of substance abusers and, 143, 152
  - neocortical dendritic atrophy and, 312
- Nitric oxide, NMDA receptors and, 310
- NMDA (*N*-methyl-D-aspartate)
- depolarization in rat hippocampal slices and, 237
  - ischemia and, 3
- NMDA antagonist
- head trauma and, 298
  - head-injured patients and, 262
  - magnesium as, 315
  - remacemide and, 248, 322
  - safety and, 249
- NMDA channel blocker, CNS 1102 as, 273
- NMDA receptor
- adenosine and, 164
  - amphetamine's interactions with, 309
  - CNS 1102 and, 279, 336
  - magnesium and, 315
  - Parkinson's disease and, 327
  - sensitization and desensitization of, 320
- Noncompetitive antagonist, CNS 1102 as, 287
- Neuroprotective agents, clinical potential for use of, 1
- O**xidative brain damage, caloric reduction and, 308
- Oxidative stress, hyperthermia and, 98
- Oxygen radicals, dorsal root ganglion hypoxia model and, 111
- P**-channels, 120
- P3, substance abusers and, 152
- Parkinson's disease
- models of, 244
  - NMDA antagonists in, 14
  - NMDA receptor participation in, 327
- Pathophysiology and therapeutic intervention, 304
- Periischemic period, hypocapnia and, 86
- Perinatal brain injury, 304
- Pharmacokinetics, dextrophan, 255
- Phospholipase A<sub>2</sub>, 341
- Placebo effects, 138
- Placental insufficiency, 28

- Polymorphonuclear leukocytes, brain injury and, 64
- Principal components analysis, ERP and, 154
- Prophylactic pharmacologic neuroprotection, focal cerebral ischemia and, 21
- Protein kinase C, 125
- Protooncogene expression, reactive oxygen species and, 340

**Q**uantitative histological evaluation, neuroprotective compounds and, 47

**R**apid superfusion system,  $^3\text{H}$ -glutamate release and, 221

Reactive oxygen species, protooncogene expression and, 340

Reflex sympathetic dystrophy, C fiber activity in, 15

Remacemide hydrochloride  
acute ischemic stroke and, 322  
mechanism of action of, 236  
Sprague-Dawley rats and, 330

Risk assessment  
biologically based dose-response model for, 339  
biomarkers and, 209  
strategies of, 198

Ro-01-6794/706, safety of, 249

**S**-PBN, free radical generation and, 102  
Safety and tolerability, dextrorphan and, 251

Safety evaluation programs, novel therapeutics and, 319

Safety-factor approach, 201

Silver impregnation of degenerative processes, 50

Small animal model, focal cerebral ischemia, 301

Sodium channels  
neuronal voltage-activated, 213  
use-dependent blockers of, 210

Spinal cord injury, methylprednisolone in, 9

Spontaneously hypertensive rats, 619C89 and, 40

Staurosporine, 125

Steriology, 49

Stress, methemoglobin production and, 136

Striatal slices, glutamate from, 75

Stroke

CGS 19755 and, 272

CNS 1102 and, 287

magnesium and, 315

Stroke rate, annual, 22

Subarachnoid hemorrhage

calcitonin gene-related peptide and, 299

models of, 243

vasospasm in, 6

Substance abuse

EEG activity in, 14

nimodipine and, 143, 152

Superoxide, 184

Surgical retraction injury, 11

Systolic blood pressure, dextrorphan and, 258

**T**-channels, 120

Taurine, release of, from cultured glia, 78

Tetrodotoxin, use-dependent channel block and, 219

Therapeutics, novel, safety evaluation programs for, 319

Transcranial Doppler (TCD) ultrasound, 280

Transforming growth factor  $\beta_1$  (TGF $\beta_1$ ), hypoxic-ischemic brain injury and, 306

Traumatic brain injury, EAA antagonist therapy in, 6

Trimethyltin, axon terminal degeneration and, 54

Tumor necrosis factor alpha (TNF $\alpha$ ), brain injury and inflammation and, 62

**U**-74689F, dexamethasone and, 185  
Use-dependent blockers, 210

**V**erapamil, cerebral blood flow and, 334  
Veratridine, 126

Vitamin E, methamphetamine-induced neurotoxicity and, 311

Voltage sensitive sodium channels, 39

Volunteers, healthy

619C89 and, 324

CNS 1102 in, 287, 337

**“W**eibel's Bible,” 47

# Index of Contributors

**A**lbers, G. W., 249-261

Ali, S. F., 311, 338

Arvin, B., 62-71

Atkinson, R., 249-261

**B**amford, J., 317-318

Bär, P. R., 111-115

Barone, F. C., 62-71

Beal, M. F., 100-110

Beenhakker, M., 163-178

Beilharz, E., 306-307

Bell, B. A., 299-300, 301-302

Berlove, D., 210-229

Biegon, A., 314

Binienda, Z., 28-38

Borrelli, A. R., 236-247

Bowyer, J. F., 72-85, 309-310, 338

Bredesen, D. E., 340

Bullock, R., 262-271, 272-278, 290-297

Burton, D., 312-313

**C**arter, M. F., 163-178

Case, K. R., 330-331

Cavagnaro, J. A., 319

Chen, J., 210-229

Choi, K. T., 86-97

Chung, J. K., 86-97

Clifton, G., 332-333

Cregan, E. F., 236-247

Curry, S., 330-331

**D**aly, D., 210-229

Davies, D. L., 72-85

Durant, G. J., 210-229

Dvorak, R., 312-313

**E**isman, M. S., 330-331

**F**euerstein, G. Z., 62-71

Fischer, J. B., 210-229

Forster, M. J., 308

Fossom, L. H., 320-321

**G**aylor, D. W., 198-208, 339

George, C. F., 328-329

Gluckman, P., 304-305, 306-307

Goldin, S. M., 210-229

Graham, S. H., 210-229

Grieffey, K. I., 230-235

Grosset, D. G., 279-289, 336-337

Guan, J., 306-307

Gunn, A., 304-305

Guo, X., 143-151, 152-159

**H**amilton, S. J. C., 328-329

Herning, R. I., 143-151, 152-159

Hobbiger, S., 324-326, 328-329

Holland, J. P., 301-302

Holson, R. R., 338

Holt, W. F., 210-229

Hoover, L., 312-313

Hu, L.-Y., 210-229

Hussein, Z., 324-326

**I**saacson, R. L., 134-142

**J**acobson, K. A., 163-178

Johnston, B., 304-305

Jonas, S., 21-25

**K**atz, P., 249-261

Kelley, R. E., 249-261

Kertesz, A., 317-318

Kim, H. K., 86-97

Knapp, A. G., 210-229

Kulkarni, S. K., 327

Kuntz, N., 312-313

Kwak, C. S., 86-97

**L**al, H., 308

Lamb, R. J., 324-326

Lange, W. R., 143-151, 152-159

Leach, M. J., 39-46

Lees, K. R., 279-289, 315-316, 317-318, 322-323, 328-329, 336-337

Lehr, L., 249-261

Lesko, L. M., 249-261

Lin, R. C-S., 163-178

Lipe, G. W., 72-85

Liu, J., 119-133

Liu, S., 319

Lunnon, M. W., 328-329

**M**agar, S., 210-229

Magni, G., 249-261

Mahmood, N. A., 330-331

Mallard, C., 304-305

Margolin, L. D., 210-229

Marks, K., 304-305

Marler, M. R., 330-331

Marmarou, A., 290-297

Matthews, J. C., 72-85

McCarthy, D. J., 330-331

McNeill, H., 306-307

Mercer, A. J., 324-326

Mervis, R. F., 312-313

Miller, O., 306-307

Modi, M., 249-261

Muir, K. W., 279-289, 315-316, 322-323, 328-329, 336-337

Myseros, J. S., 262-271, 290-297

Neville, L. F., 62-71  
Newport, G. D., 338

Palmer, G. C., 236-247  
Paul, K., 249-261  
Perlman, M. E., 210-229  
Pitman, V., 249-261  
Posner, J., 324-326  
Pryse-Phillips, W., 317-318

Rae, J., 249-261  
Reddy, N. L., 210-229  
Rosenbaum, D. M., 249-261  
Rutledge, A., 119-133

Sarafian, T., 340  
Scallet, A. C., 47-58, 72-85, 303  
Schoepp, D. D., 230-235  
Schulz, J. B., 100-110  
Sharma, R., 210-229  
Sirimanne, E., 306-307  
Skolnick, P., 320-321  
Slikker, W., Jr., xi, 198-208, 338, 339  
Sohal, R. S., 308  
Solomon, P. R., 312-313  
Squire, I. B., 317-318  
Stewart, L., 332-333

Subbarao, K., 210-229  
Swan, J. H., 39-46

Tan, W., 304-305  
Tandon, R., 312-313  
Teasdale, G. M., 332-333  
Tizzano, J. P., 230-235  
Trembly, B., xi, 1-20  
Triggle, D. J., 119-133  
Tuor, U. I., 179-195

Varner, J. A., 134-142  
Verity, M. A., 340, 341  
Verma, A., 327  
von Lubitz, D. K. J. E., 163-178

Wagstaff, A., 332-333  
Weinstein, G. B., 334-335  
Willett, F., 236-247  
Williams, C., 304-305, 306-307  
Wood, M. S., 312-313  
Woodward, J. J., 290-297

Yoo, K., 249-261  
Young, H. F., 290-297

Zauner, A., 290-297

